Results 101 to 110 of about 1,228 (155)

Delafloxacin: First Global Approval

, 2018
Compliance with Ethical Standards.Funding: The preparation of this review was not supported by any external funding.Conflicts of interest: A. Markham is a contracted employee of Adis/Springer, is responsible for the article content and declares no ...
Anthony Markham (4891627)
core   +1 more source

Molecular dynamics simulation guided analysis of the interaction between delafloxacin and Staphylococcus aureus gyrase mutants

Staphylococcus aureus is a highly virulent nosocomial pathogen producing a wide array of virulence factors to orchestrate a deadly disease. Delafloxacin is a fluoroquinolone antibiotic targeting gyrase to confer its antibacterial properties by ...
Subhadip Saha (13206937), Monidipa Ghosh (13206943), Harshita Tiwari (9500384)   +2 more
core   +1 more source

Susceptibility of multidrug-resistant Escherichia coli and Klebsiella pneumoniae to oral antibiotics in Australia

Journal of Global Antimicrobial Resistance
: Objectives: In Australia, resistance to β-lactam-class antibiotics in Enterobacterales has increased. This study aimed to identify potential oral treatments for these multidrug-resistant infections by investigating four β-lactam (mecillinam, tebipenem,
Bethany Rachel O'Neill, Andrew Ginn, Menuk Jayawardena, Indy Sandaradura   +3 more
doaj   +1 more source

Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections

, 2017
In the era of multi-drug resistant pathogens, the adequate treatment of skin and skin structure infections remains a challenge for clinicians. Delafloxacin, with its broad spectrum against Gram-positive, Gram-negative and anaerobic organisms, represents ...
Righi, Elda, Federico Pea, Cojutti, Piergiorgio, Davide Pecori, PECORI, DAVIDE, Pecori, D., BASSETTI, MATTEO, Pea, Federico, Piergiorgio Cojutti, Righi, E., Matteo Bassetti, Cojutti, P., Elda Righi, Bassetti, M., Pea, F.   +14 more
core   +1 more source

Delafloxacin in Acute Bacterial Skin and Skin Structure Infections [PDF]

Clinical Infectious Diseases, 2019
Corey, G Ralph, McKinnell, Jamie A, Rybak, Michael J   +2 more
openaire   +2 more sources

Evaluation of in vitro activity of delafloxacin against Staphylococcus aureus MSSA and MRSA isolated from a Brazilian tertiary hospital. [PDF]

Braz J Microbiol
Barth PO, Ucha LR, Lutz L, Barth AL.
europepmc   +1 more source

Genome-wide network of antibiotic susceptibility in Pseudomonas aeruginosa. [PDF]

J Antimicrob Chemother
Goncalves O, Côté JP.
europepmc   +1 more source

<i>Staphylococcus pettenkoferi</i>: an underrecognized species with clinically relevant antimicrobial resistance. A comprehensive genomic European study. [PDF]

Emerg Microbes Infect
Magnan C, Curtil-Dit-Galin M, Morsli M, Cattoir V, Piau-Couapel C, Söderquist B, Kahl BC, Denis O, Rwayane K, Corvec S, François P, Salipante F, Pantel A, Dunyach-Remy C, Laurent F, Lavigne JP, European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Study Group for Staphylococci and Staphylococcal Diseases (ESGS).   +16 more
europepmc   +1 more source

Synergistic beeswax-based nano-formulation for enhanced chronic wound healing and antibacterial potency. [PDF]

RSC Adv
Eid AM, Alawami AS, Allam AA, Mahgoub SM, Soliman AG, Shahin N, M M R, Mahmoud R.   +7 more
europepmc   +1 more source

Novel Antibiotics and Emerging Resistance:&nbsp;<i>In Vitro</i>&nbsp;Activity of Five Antimicrobials Against Intensive Care Unit Isolates from a Turkish Tertiary Care Hospital. [PDF]

Infect Dis Clin Microbiol
Kutlu HH, Akdoğan-Kittana FN, Günaydın B, Özkılıç Y.   +3 more
europepmc   +1 more source